The verdict
Our read at a glance.
Whether VYLEESI / bremelanotide evidence supports a narrow approved-context HSDD claim without extending to generic PT-141, off-label use, sexual-performance narratives, or identity-uncertain market products.
- The signal
- This memo draws on 42 exact bremelanotide/PT-141/VYLEESI sources, after excluding context-only and unreliable-history records. FDA, DailyMed, openFDA, FDA review documents, ClinicalTrials.gov records, and peer-reviewed HSDD studies support a product-specific approved-use signal, but the main efficacy evidence is modest, patient-reported, sponsor-linked, and contested by endpoint and tolerability critiques. Older PT-141 studies in male or early female sexual-function contexts are historical investigational records only, not current approved-use evidence.
- The unknown
- How durable benefit-risk looks outside the studied approved-product context, how future registry and post-market information changes the safety picture, and how reliably public sources can keep VYLEESI evidence separate from generic PT-141, compounded, research-use, internet-market, melanotan, alpha-MSH, afamelanotide, setmelanotide, KPV, and broad melanocortin claims.
- Our read
- Approved specific use, not a broad libido or performance peptide. The strongest read is that VYLEESI has regulator-reviewed evidence in a narrow HSDD setting, while generic PT-141 and identity-uncertain products remain product-identity and safety-watch territory.
The mechanism
How it works.
Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors in the brain, mainly MC4R, rather than acting on blood vessels. By stimulating central pathways that govern sexual desire and arousal, it works upstream in the brain, a different route from erectile-dysfunction drugs like sildenafil, which boost genital blood flow through the PDE-5 pathway. This established central mechanism underlies the approved VYLEESI product for low sexual desire in women, and is separate from generic or compounded PT-141 sold for other uses.
Safety & regulatory boundary
The consequential part.
VYLEESI / bremelanotide evidence should not be treated as equivalent to generic PT-141, compounded products, research-use products, internet-market products, identity-uncertain market products, Melanotan II, alpha-MSH, Melanotan I / afamelanotide, setmelanotide, KPV, or broad melanocortin biology. Label and FDA-review safety boundaries include cardiovascular-parameter effects, nausea and discontinuation/tolerability concerns, pigmentation changes, pregnancy and lactation uncertainty, and product-identity limitations.
What's next
What we're watching.
Watch FDA/DailyMed label changes, FDA review updates, exact ClinicalTrials.gov records, peer-reviewed follow-up from completed HSDD and safety studies, lactation or pregnancy-related evidence, critical reanalyses of patient-reported endpoints, and any exact regulator product records that can be cited without relying on search-page absence claims.
Context
Why this is discussed.
PT-141 is widely discussed online because bremelanotide has melanocortin-pathway pharmacology and an FDA-approved product exists. That attention creates high claim-scope risk: VYLEESI evidence is product-, label-, population-, and endpoint-specific, while public discussion often blurs it with generic PT-141, melanotan analogs, compounded products, research-use products, and broad sexual-function claims.
The evidence base
42 cited references.
Regulatory & labels8
Food and Drug Administration · 2019-06-21
National Library of Medicine / FDA label · Revised 2024-03; checked 2026-05-17
Food and Drug Administration / openFDA · Checked 2026-05-17
Food and Drug Administration · 2019
Food and Drug Administration · 2019-06-14
Food and Drug Administration · 2019
Food and Drug Administration · 2019
Food and Drug Administration · 2019-06-21
Registered trials10
ClinicalTrials.gov / Palatin Technologies · Completed 2017; results posted 2020
ClinicalTrials.gov / Palatin Technologies · Completed 2017
ClinicalTrials.gov / Palatin Technologies · Completed 2012
ClinicalTrials.gov / Palatin Technologies · Completed
ClinicalTrials.gov / PNS Pharmaceutical · Completed
ClinicalTrials.gov / Imperial College London · Completed
ClinicalTrials.gov / AMAG Pharmaceuticals · Completed
ClinicalTrials.gov / Cosette Pharmaceuticals · Completed
ClinicalTrials.gov / Palatin Technologies · Completed
ClinicalTrials.gov / Palatin Technologies · Active not recruiting; checked 2026-05-17
Peer-reviewed journals7
White WB et al. · 2017
Koochaki PE et al. · 2021
Spielmans GI · 2021
Diamond LE et al. · 2004
Pfaus JG et al. · 2004
Pfaus JG, Giuliano F, Gelez H · 2007
Thurston L et al. · 2022
Indexed literature (PubMed)12
Kingsberg SA et al. · 2019
Simon JA et al. · 2019
Clayton AH et al. · 2016
Diamond LE et al. · 2006
Parish SJ et al. · 2022
Clayton AH et al. · 2022
Spielmans GI, Ellefson RA · 2024
Rosen RC et al. · 2004
Diamond LE et al. · 2005
Molinoff PB et al. · 2003
Zhang X et al. · 2021
PubMed-indexed authors · 2025
Sponsor & other sources5
National Library of Medicine · Updated 2019-08-28
National Center for Biotechnology Information · Checked 2026-05-17
IUPHAR/BPS Guide to Pharmacology · Checked 2026-05-17
National Library of Medicine / RxNav · Checked 2026-05-17
National Institute of Diabetes and Digestive and Kidney Diseases · Updated public record
Keep reading